BRAF and colorectal cancer: To evaluate whether BRAFV600E PMP models behaved as colorectal cancer in response to encorafenib treatment, we treated BRAF wild type (BRAFWT) colorectal cancer (T70), BRAFV600E colorectal cancer (CTAX34), and two BRAFV600E PMP organoid models derived from two PM lesions from patient 5 (PDXO PMP5.1 and PDO PMP5.2) with control, mitomycin C, cetuximab, encorafenib, or doublet and evaluated cell viability at different time points.